In recent years, we have demonstrated that a number of TKIs, including lapatinib [12], alectinib [13] and apatinib [14], can be used to potentiate the efficacy of anticancer drugs in MDR cancer cells by inhibiting ABC transporters. The gene discussed is ABCG2; the disease is cancer.